The BCL2 inhibitor venetoclax has recently emerged as an important component of acute
myeloid leukemia (AML) therapy. Notably, use of this agent has revealed a previously …

Acute myeloid leukemia (AML) is a disease that mainly affects elderly patients who are more
often unfit for intensive chemotherapy (median age of diagnosis is 68). The regimens …

Simple Summary Venetoclax–azacitidine is a new standard for elderly or unfit acute myeloid
leukemia patients. Nevertheless, resistance remains a matter of concern. The main genetic …

Leukemia can arise at various stages of the hematopoietic differentiation hierarchy, but the
impact of developmental arrest on drug sensitivity is unclear. Applying network-based …

Simple Summary GATA2 deficiency is a complex disorder associated with an increased risk
for myelodysplastic syndrome (MDS) and acute myeloid leukemia. In this study, we focused …

Venetoclax, an oral BCL‐2 inhibitor, has been widely incorporated in the treatment of acute
myeloid leukaemia. The combination of hypomethylating agents and venetoclax is the …

Myelomonocytic and monocytic acute myeloid leukemia (AML) subtypes are intrinsically
resistant to venetoclax-based regimens. Identifying targetable vulnerabilities would limit …

Neuroendocrine carcinomas (NECs) are extremely lethal malignancies that can arise at
almost any anatomic site. Characterization of NECs is hindered by their rarity and significant …

Background. Primary resistance of acute myeloid leukemia (AML) to the conventional 3+ 7
intensive chemotherapy and relapses after first-line chemotherapy are two highly …

The diagnostic spectrum for AML patients is increasingly based on genetic abnormalities
due to their prognostic and predictive value. However, information on the AML blast …